Wei Gao
Boston
Education
Ph.D., biostatistics, Boston University; M.S., biostatistics, The George Washington University; B.S., mathematics, Fudan University
Summary of Experience
Dr. Gao specializes in developing innovative statistical methodologies and applying them to the study of clinical and economic outcomes in a broad range of disease areas. He has led and implemented analyses across entire product lifecycles, from early-phase clinical trials to post-market real-world evidence generation. Dr. Gao has particular expertise in retrospective data and clinical trial data analysis, health economics modeling, indirect treatment comparisons, predictive analytics, meta-analyses, individualized medicine, and statistical genetics. His research has supported the launches of several pharmaceutical products and has been widely published in leading peer-reviewed journals, including The New England Journal of Medicine, JAMA, Nature Genetics, Nature Communications, and the American Journal of Respiratory and Critical Care Medicine. He has presented his work at multiple statistical and health care conferences.
Selected Publishing
-
Integrating real-world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women
Clinical and Translational Science, 2021
2021Beck D, Winzenborg I, Gao W, Mostafa NM, Noertersheuser P, Chiuve SE, Owens C, Shebley M
-
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma
Clinical Genitourinary Cancer, 2020
2020Cao X, Tang D, Ratto B, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ
-
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
Clinical Drug Investigation, 2020
2020Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R
-
Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population
JBMR Plus, 2020
2020Kilpatrick RD, Chiuve SE, Leslie WD, Wegrzyn LR, Gao W, Yang H, Soliman AM, Snabes MC, Koenigsberg S, Zhong J, Xiang C, Watts NB
-
Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia
Expert Review of Pharmacoeconomics & Outcomes Research, 2020
2020Mowitz ME, Mangili A, Han L, Ayyagari R, Gao W, Wang J, Zhao J, Sarda SP
-
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
Gynecologic Oncology, 2020
2020Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K
-
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
Pharmacoeconomics, 2020
2020Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB
-
Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain
Journal of Medical Economics, 2019
2019Vo P, Gao W, Zichlin ML, Fuqua E, Fadli E, Vazquez MA, Tarancón T, Mahieu N, Maier-Peuschel M, Rossi S, Naclerio M, Ritrovato D, Swallow E
-
Migraine-related healthcare resource use in the emergency department setting: a panel-based chart review in France, Germany, Italy, and Spain
Journal of Medical Economics, 2019
2019Vo P, Gao W, Zichlin ML, Fuqua E, Fadli E, Vazquez MA, Tarancón T, Mahieu N, Maier-Peuschel M, Rossi S, Naclerio M, Ritrovato D, Swallow E
-
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Advances in Therapy, 2019
2019Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S
-
Health Care Burden of Bronchopulmonary Dysplasia Among Extremely Preterm Infants
Frontiers in Pediatrics, 2019
2019Mowitz ME, Ayyagari R, Gao W, Zhao J, Mangili A, Sarda SP
-
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Journal of Medical Economics, 2019
2019Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibáñez R
-
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
Journal of Blood Medicine, 2019
2019Batt K, Gao W, Ayyagari R, Deschaseaux C, Vashi PB, Yao Z, Wang Y, Kessabi S, Klamroth R
News
-
March 29, 2022
-
June 4, 2021
-
October 22, 2019